Orion Platform imaging for tumor-immune interactions
4 Jun 2024Deeper understanding of the intricacies between tumor microenvironments and immune cell infiltrates is critical for creation of next generation therapies. In this scientific poster, RareCyte presents a single-step 15-plex fluorescence immunohistochemistry (IHC) protocol using the Orion platform to analyze tumor microenvironments and immune cell phenotypes across multiple tumor types. The poster highlights a study aimed to enhance biomarker analysis by utilizing formalin-fixed paraffin-embedded (FFPE) tumor microarrays. The results demonstrate that the Orion platform can efficiently detect 15 distinct biomarkers on a single slide, surpassing traditional methods limited to 6 markers. The method offers significant workflow advantages, reducing tissue and signal loss, and potentially leading to better diagnostic and therapeutic outcomes by providing deeper insights into immune surveillance and mechanisms of resistance in various cancers.
Related Products
Request Quote for All Products
Orion Biomarkers
RareCyte, IncOrion Biomarkers are tailored to enable spatial biomarker analysis with maximum flexibility. Choose from a range of labeled antibodies to generate Orion spatial biology data for multiplexed tissue imaging or create new reagents with easy-to-use conjugation kits.
Orion Multiplex Imaging Instrument
RareCyte, IncThe Orion Platform delivers spatial biology and cellular phenotyping at a speed and resolution needed for translation from research to the clinic. It utilizes single round immunofluorescence staining and imaging of standard FFPE or fresh frozen tissue to deliver subcellular quantitation of biomarker targets across a whole slide in only a few hours. Combining speed and resolution with the additional benefits of industry-standard H&E and IHC modes, comprehensive phenotypic profiling of patient cohorts can be generated for characterization of tissue architecture, tumor heterogeneity, and the immune response. Use your own antibodies, run panels from an extensive biomarker list, or engage RareCyte services for custom panels and programs.